Building a proactive strategy for navigating regulatory complexity in CGT development and commercialization
The rapid advancement of cell and gene therapies (CGT) has created a dynamic regulatory environment that is complex and can be difficult to navigate. The lack of precedent and established frameworks for novel and evolving formats makes regulatory compliance especially difficult for biopharmaceutical manufacturers.
Enter your information to access strategies that can help you better understand how to fulfill your regulatory obligations and help avoid delays in commercialization.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.